Selexipag for the treatment of pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Selexipag for the treatment of pulmonary arterial hypertension

Published:2017-08-01 Issue:15 Volume:74 Page:1135-1141
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Noel Zachary R.¹,Kido Kazuhiko²,Macaulay Tracy E.³

Affiliation:

1. Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD

2. Department of Pharmacy Practice, South Dakota State University, Sioux Falls, SD, and Department of Pharmacy, Avera McKennan Hospital, Sioux Falls, SD

3. Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY, and UKHealthCare Jack and Linda Gill Heart Institute, Lexington, KY

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/74/15/1135/28336342/ajhp1135.pdf

Reference26 articles.

1. An epidemiological study of pulmonary arterial hypertension;Peacock;Eur Respir J.,2007

2. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies;Archer;Circulation.,2010

3. Pulmonary arterial hypertension;Montani;Orphanet J Rare Dis.,2013

4. Pulmonary arterial hypertension;Farber;N Engl J Med.,2004

5. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report;Taichman;Chest.,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential drug response in pulmonary arterial hypertension: The potential for precision medicine;Pulmonary Circulation;2023-10

2. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report;ESC Heart Failure;2023-06-19

3. Long-Term Experience and Safety of Transitioning from Subcutaneous Treprostinil to Oral Selexipag in the High-Risk Pulmonary Hypertension Patient: A Case Report;ACTA CARDIOL SIN;2023

4. The use of selexipag, a prostacyclin receptor analog, for treatment of severe pulmonary artery hypertension during pregnancy, a case report;Respiratory Medicine Case Reports;2023

5. Pulmonary Arterial Hypertension in Connective Tissue Diseases Beyond Systemic Sclerosis;Heart Failure Clinics;2023-01